+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

African Trypanosomiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 71 Pages
  • April 2022
  • Region: Africa
  • Global Markets Direct
  • ID: 5589938
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide African Trypanosomiasis - Drugs In Development, 2022, provides an overview of the African Trypanosomiasis (Infectious Disease) pipeline landscape.

African trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to humans through the bite of the tsetse fly. Symptoms include anxiety, drowsiness during the day, fever, headache, insomnia at night, mood changes, sleepiness (may be uncontrollable), sweating, swollen lymph nodes all over the body, swollen, red, painful nodule at site of fly bite and weakness. Treatment includes anti-protozoal agents.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide African Trypanosomiasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for African Trypanosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The African Trypanosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 5 and 3 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 5 and 3 molecules, respectively.

African Trypanosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of African Trypanosomiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for African Trypanosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in African Trypanosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates African Trypanosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for African Trypanosomiasis (Infectious Disease)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for African Trypanosomiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding African Trypanosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionReport CoverageAfrican Trypanosomiasis - Overview
African Trypanosomiasis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
African Trypanosomiasis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
African Trypanosomiasis - Companies Involved in Therapeutics DevelopmentAfrican Trypanosomiasis - Drug ProfilesAfrican Trypanosomiasis - Dormant ProjectsAfrican Trypanosomiasis - Discontinued ProductsAfrican Trypanosomiasis - Product Development Milestones
Featured News & Press Releases
  • Jul 19, 2021: US FDA approves fexinidazole as the first all-oral treatment for sleeping sickness
  • Feb 02, 2021: PaxMedica receives FDA orphan drug designation for use of PAX-101 (IV suramin) in a rare tropical disease
  • Nov 16, 2018: Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
  • Nov 16, 2018: CHMP recommends first oral-only treatment for sleeping sickness
  • Jan 31, 2018: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment
  • Nov 04, 2017: Phase II/III Studies Show High Efficacy and Safety of Fexinidazole, the First Oral Treatment for Sleeping Sickness
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for African Trypanosomiasis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • African Trypanosomiasis - Pipeline by Cesa Alliance SA, 2022
  • African Trypanosomiasis - Pipeline by F. Hoffmann-La Roche Ltd, 2022
  • African Trypanosomiasis - Pipeline by GlaxoSmithKline Plc, 2022
  • African Trypanosomiasis - Pipeline by MediSynergics LLC, 2022
  • African Trypanosomiasis - Pipeline by Novartis AG, 2022
  • African Trypanosomiasis - Pipeline by Paxmedica Inc, 2022
  • African Trypanosomiasis - Pipeline by Pfizer Inc, 2022
  • African Trypanosomiasis - Pipeline by Sanofi, 2022
  • African Trypanosomiasis - Pipeline by Scynexis Inc, 2022
  • African Trypanosomiasis - Pipeline by Synstar Japan Co Ltd, 2022
  • African Trypanosomiasis - Dormant Projects, 2022
  • African Trypanosomiasis - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for African Trypanosomiasis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Targets, 2022
  • Number of Products by Stage and Targets, 2022
  • Number of Products by Mechanism of Actions, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Cesa Alliance SA
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • MediSynergics LLC
  • Novartis AG
  • Paxmedica Inc
  • Pfizer Inc
  • Sanofi
  • Scynexis Inc
  • Synstar Japan Co Ltd